A Phase 1 Study of ATV-1601 in Patients With Advanced Cancer That Have AKT1 E17K Mutations
Atavistik Bio, Inc
Atavistik Bio, Inc
K36 Therapeutics, Inc.
Alterome Therapeutics, Inc.
Elevation Oncology
Plus Therapeutics
Engeneic Pty Limited
Advanced Accelerator Applications
Revolution Medicines, Inc.
Endocyte
Poseida Therapeutics, Inc.
Blueprint Medicines Corporation
Blueprint Medicines Corporation
Revolution Medicines, Inc.
Advaxis, Inc.
Aragon Pharmaceuticals, Inc.
Sumitomo Pharma America, Inc.
Blueprint Medicines Corporation
Revolution Medicines, Inc.
Syndax Pharmaceuticals
Bristol-Myers Squibb
AVEO Pharmaceuticals, Inc.
Pharmacyclics LLC.